Tagrisso for lung cancer gets full approval in Europe

25 April 2017
astrazeneca-large

Anglo-Swedish pharma major AstraZeneca (LSE: AZN) has been given full marketing authorization in Europe for Tagrisso (osimertinib) as a therapy against a particular kind of non-small cell lung cancer (NSCLC).

The decision is based on the results of a Phase III trial in which the drug showed statistically-significant improvements in survival rates compared with standard chemotherapy, in 419 patients.

The approval applies to patients with locally-advanced or metastatic ‘EGFR T790M mutation-positive’ NSCLC, a type which affects 10%-15% of NSCLC patients in the USA and Europe, and 30%-40% of patients in Asia.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical